Research on the inhibition of Treg cells on MMP-9 in rheumatoid arthritis with acute cerebral ischemia

Abstract

Abstract:

Recent studies have found that patients with rheumatoid arthritis (RA) are more likely to suffer from acute cerebral ischemia and other cardiovascular diseases than healthy people. RA further aggravated the development of acute cerebral ischemia. Matrix metalloproteinase-9 (MMP-9) may degrade the extracellular matrix, the damage of blood-brain barrier, the infiltration of inflammatory cells and pro-inflammatory cytokine. MMP-9 helps to build the series-wound amplifiers of inflammatory cascade reaction after cerebral ischemia. Treg cells can inhibit MMP-9 activity through multiple pathways to control acute cerebral ischemia and alleviate the symptoms of RA. First, Treg cells inhibit the activity of MMP-9 by blocking NF-κB pathway; Second, Treg cells can inhibit MMP-9 by regulating the expression of TGF-β1 and TNF-α; Third, Treg cells transform the polarization type of microglia/macrophage activated by acute cerebral ischemia to prevent MMP-9's secretion and the reinforce the immune tolerance of M2 microglia/macrophages; Fourth, Treg cells release anti-inflammatory cytokines to antagonize Th17 cells, to regulate immune balance and to alleviate inflammation induced by RA with acute cerebral ischemia. This article reviewed the therapeutic effects of Treg cells in treating RA with acute cerebral ischemia by inhibiting the activity of MMP-9 in hope of providing a reference for the effective treatment and research of RA with acute cerebral ischemia.

Key words: rheumatoid arthritis, acute cerebral ischemia, regulatory T cells, matrix metalloprotein-9

CLC Number:

R684.3| R743.31

SHEN Chen, LI Yunman, XIA Nian, XU Dan, HAN Dan, CHEN Shijie. Research on the inhibition of Treg cells on MMP-9 in rheumatoid arthritis with acute cerebral ischemia[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 831-840.

References

［1］许军峰, 张浪, 田骞, 等. 针刺对脑缺血再灌注大鼠皮质缺血半暗带细胞超微结构的影响［J］. 长春中医药大学学报, 2016, 32(3): 455-457.
［2］Primdahl J, Clausen J, Hrslev-Petersen K. Results from systematic screening for cardiovascular risk in outpatients with rheumatoid arthritis in accordance with the EULAR recommendations［J］. Ann Rheum Dis, 2013, 72(11): 1771-1776.
［3］Rosales-Alexander JL, Salvatierra J, Llorca J, et al. Cardiovascular risk assessment in rheumatoid arthritis: impact of the EULAR recommendations on a national calibrated score risk index［J］. Clin Exp Rheumatol, 2014, 32(2): 237-242.
［4］Eriksson JK, Jacobsson L, Bengtsson K, et al. Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis ［J］? Ann Rheum Dis, 2017, 76(2): 364-370.
［5］Sakai R, Hirano F, Kihara M, et al. High prevalence of cardiovascular comorbidities in patients with rheumatoid arthritis from a population-based cross-sectional study of a Japanese health insurance database［J］. Mod Rheumatol, 2016, 26(4):522-528.
［6］Lindhardsen J,Ahlehoff O,Gislasen Gh, 等. 类风湿性关节炎患者脑卒中和心房颤动风险将增加［J］. 心血管病学进展, 2013, 34(2): 296.
［7］葛秀兰, 冯志杰. 类风湿性关节炎并发尿崩症、脑梗塞、间质性肺炎及虹膜炎(附1例报告)［J］. 河北医学院学报, 1989, 10(3): 173,175.
［8］王鹏, 余旻, 王嘉军. 基质金属蛋白酶-9与全身炎症反应综合征研究进展［J］. 现代生物医学进展, 2012, 12(5): 998-1000.
［9］Gan X, Wong B, Wright SD, et al. Production of matrix metalloproteinase-9 in CaCO-2 cells in response to inflammatory stimuli［J］. J Interferon Cytokine Res, 2001, 21(2): 93-98.
［10］Mudge SJ, Paizis K, Auwardt RB, et al. Activation of nuclear factor-kappa B by podocytes in the autologous phase of passive Heymann nephritis［J］. Kidney Int, 2001, 59(3): 923-931.
［11］Li W, Li H, Bocking AD, et al. Tumor necrosis factor stimulates matrix metalloproteinase 9 secretion from cultured human chorionic trophoblast cells through TNF receptor 1 signaling to IKBKB-NFKB and MAPK1/3 pathway［J］. Biol Reprod, 2010, 83(3): 481-487.
［12］Long M, Park SG, Strickland I, et al. Nuclear factor-kappaB modulates regulatory T cell development by directly regulating expression of Foxp3 transcription factor［J］. Immunity, 2009, 31(6): 921-931.
［13］Venet F, Pachot A, Debard AL, et al. Human CD4+CD25+ regulatory T lymphocytes inhibit lipopolysaccharide-induced monocyte survival through a Fas/Fas ligand-dependent mechanism［J］. J Immunol, 2006, 177(9): 6540-6547.
［14］Shono Y, Tuckett AZ, Ouk S, et al. A small-molecule c-Rel inhibitor reduces alloactivation of T cells without compromising antitumor activity［J］. Cancer Discov, 2014, 4(5): 578-591.
［15］Sasano H, Suzuki T, Miki Y, et al. Intracrinology of estrogens and androgens in breast carcinoma［J］. J Steroid Biochem Mol Biol, 2008, 108(3-5): 181-185.
［16］Uhlirova M, Bohmann D. JNK‐ and Fos‐regulated Mmp1 expression cooperates with Ras to induce invasive tumors in Drosophila［J］. Embo J, 2006, 25(22): 5294-5304.
［17］Meisser A, Chardonnens D, Campana A, et al. Effects of tumour necrosis factor-alpha, interleukin-1 alpha, macrophage colony stimulating factor and transforming growth factor beta on trophoblastic matrix metalloproteinases［J］. Mol Human Rep, 1999, 5(3): 252-260.
［18］Han YP, Tuan TL, Hughes M, et al. Transforming growth factor-beta - and tumor necrosis factor-alpha-mediated induction and proteolytic activation of MMP-9 in human skin［J］. J Biol Chem, 2001, 276(25): 22341-223450.
［19］Bain JM, Ziegler A, Yang Z, et al. TGFβ1 Stimulates the over-production of white matter astrocytes from precursors of the “brain marrow” in a rodent model of neonatal encephalopathy［J］. Plos One, 2012, 5(3): e9567.
［20］Sen T, Chatterjee A. 8526 POSTER fibronectin induces matrix metalloproteinase-9 (MMP-9) in human laryngeal carcinoma cells by involving multiple signaling pathways［J］. Biochimie, 2011, 47(10): 1422-1434.
［21］Rosenberg GA, Cunningham LA, Wallace J, et al. Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures［J］. Brain Res, 2001, 893(2): 104-112.
［22］Roberts CA, Dickinson AK, Taams LS. The interplay between monocytes/macrophages and CD4+T cell subsets in rheumatoid arthritis［J］. Front Immunol, 2015, 2015 Nov 19;6:571. doi: 10.3389/fimmu.2015.00571. eCollection 2015.
［23］Xie L, Choudhury GR, Winters A, et al. Cerebral regulatory T cells restrain microglia/macrophage-mediated inflammatory responses via IL-10［J］. Eur J Immunol, 2015, 45(1): 180-191.
［24］Ebner F, Brandt C, Thiele P, et al. Microglial activation milieu controls regulatory T cell responses［J］. J Immunol, 2013, 191(11): 5594-5602.
［25］Liu G, Ma H, Qiu L, et al. Phenotypic and functional switch of macrophages induced by regulatory CD4+CD25+T cells in mice［J］. Immunol Cell Biol, 2011, 89(1): 130-142.
［26］Tiemessen MM, Jagger AL, Evans HG, et al. CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages［J］. Proc Natl Acad Sci USA, 2008, 104(49): 19446-19451.
［27］Soroosh P, Doherty TA, Duan W, et al. Lung-resident tissue macrophages generate Foxp3+ regulatory T cells and promote airway tolerance［J］. J Exp Med, 2013, 210(4): 775-788.
［28］Liesz A, Suri-Payer E, Veltkamp C, et al. Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke［J］. Nat Med, 2009, 15(2): 192-199.
［29］Klebe D, Mcbride D, Flores JJ, et al. Modulating the immune response towards a neuroregenerative peri-injury milieu after cerebral hemorrhage［J］. J Neuroimmune Pharmacol, 2015, 10(4): 576-586.
［30］Brea D, Agulla J, Rodriguez-Yanez M, et al. Regulatory T cells modulate inflammation and reduce infarct volume in experimental brain ischaemia［J］. J Cell Mol Med, 2014, 18(8): 1571-1579.
［31］Savage ND, de Boer T, Walburg KV, et al. Human anti-inflammatory macrophages induce Foxp3+ GITR+ CD25+ regulatory T cells, which suppress via membrane-bound TGFbeta-1［J］. J Immunol, 2008, 181(3): 2220-2226.
［32］Patel SR. Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses［J］. Nat Immunol, 2007, 8(10): 1086-1094.
［33］Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets［J］. Nat Rev Immunol, 2011, 11(11): 723-737.
［34］Saijo K, Glass CK. Microglial cell origin and phenotypes in health and disease［J］. Nat Rev Immunol, 2011, 11(11): 775-787.
［35］Brea D, Sobrino T, Ramos-Cabrer P, et al. Inflammatory and neuroimmunomodulatory changes in acute cerebral ischemia［J］. Cerebrovasc Dis, 2009, 27 Suppl 1: 48-64.
［36］Yan J, Greer JM, Etherington K, et al. Immune activation in the peripheral blood of patients with acute ischemic stroke［J］. J Neuroimmunol, 2009, 206(1-2): 112-117.
［37］O'byrne PM, Inman MD, Adelroth E. Reassessing the Th2 cytokine basis of asthma［J］. Trends Pharmacol Sci, 2004, 25(5): 244-248.
［38］Ra HJ, Parks WC. Control of matrix metalloproteinase catalytic activity［J］. Matrix Biol, 2007, 26(8): 587-596.
［39］Turner RJ, Sharp FR. Implications of MMP9 for blood brain barrier disruption and hemorrhagic transformation following ischemic stroke［J］. Front Cell Neuro,2016,10(305):56.
［40］Kohama Y. Discovery of immature thymocyte proliferation factor［J］. Yakugaku Zasshi, 2006,126(3): 145-160.
［41］Spits H. Development of alphabeta T cells in the human thymus［J］. Nat Rev Immunol, 2002, 2(10): 760-772.
［42］周洲, 冯娟, 王宪. 调节性T细胞的分化及其影响因素［J］. 生物物理学报, 2012, 28(2): 93-111.
［43］Zheng Y, Rudensky AY. Foxp3 in control of the regulatory T cell lineage［J］. Nat Immunol, 2007, 8(5): 457-462.
［44］D'cruz LM, Klein L. Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling［J］. Nat Immunol, 2005, 6(11): 1152-1159.
［45］Karimi S, Chattopadhyay S, Chakraborty NG. Manipulation of regulatory T cells and antigen-specific cytotoxic T lymphocyte-based tumour immunotherapy［J］. Immunology, 2015, 144(2): 186-196.
［46］Ivanova EA, Orekhov AN. T helper lymphocyte subsets and plasticity in autoimmunity and cancer: an overview［J］. Biomed Res Int, 2015, 2015: 327470.
［47］Pearce EJ, Caspar P, Grzych JM, et al. Pillars article: downregulation of Th1 cytokine production accompanies induction of Th2 responses by a parasitic helminth, Schistosoma mansoni. J. Exp. Med. 1991. 173: 159-166［J］. J Immunol, 2012, 189(3): 1104-1111.
［48］Shimoda K, Van Deursen J, Sangster MY, et al. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene［J］. Nature, 1996, 380(6575): 630-633.
［49］Iwakura Y, Ishigame H, Saijo S, et al. Functional specialization of interleukin-17 family members［J］. Immunity, 2011, 34(2): 149-162.
［50］Murdaca G, Colombo BM, Puppo F. The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases［J］. Intern Emerg Med, 2011, 6(6): 487-495.
［51］Fainboim L, Arruvito L. Mechanisms involved in the expansion of Tregs during pregnancy: role of IL-2/STAT5 signalling［J］. J Reprod Immunol, 2011, 88(2): 93-98.
［52］Gu AD, Wang Y, Lin L, et al. Requirements of transcription factor Smad-dependent and -independent TGF-beta signaling to control discrete T-cell functions［J］. Proc Natl Acad Sci U S A, 2012, 109(3): 905-910.
［53］Lal G, Zhang N, Van Der Touw W, et al. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation［J］. J Immunol, 2009, 182(1): 259-273.
［54］Tao JH, Cheng M, Tang JP, et al. Foxp3, Regulatory T cell, and autoimmune diseases［J］. Inflammation, 2017, 40(1):328-339.
［55］Ikeda S, Saijo S, Murayama MA, et al. Excess IL-1 signaling enhances the development of Th17 cells by downregulating TGF-beta-induced Foxp3 expression［J］. J Immunol, 2014, 192(4): 1449-1458.
［56］Banerjee DK, Dhodapkar MV, Matayeva E, et al. Expansion of FOXP3 high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients［J］. Blood, 2006, 108(8): 2655-2661.
［57］Nie H, Zheng Y, Li R, et al. Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-alpha in rheumatoid arthritis［J］. Nat Med, 2013, 19(3): 322-328.
［58］Li N, Ma T, Han J, et al. Increased apoptosis induction in CD4+ CD25+ Foxp3+ T cells contributes to enhanced disease activity in patients with rheumatoid arthritis through IL-10 regulation［J］. Eur Rev Med Pharmacol Sci, 2014, 18(1): 78-85.
［59］Li Q, Wang Y, Yu F, et al. Peripheral Th17/Treg imbalance in patients with atherosclerotic cerebral infarction［J］. Int J Clin Exp Pathol, 2013, 6(6): 1015-1027.
［60］Pe VDS, Dubois B, Nelissen I, et al. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9)［J］. Crit Rev Biochem Mol Biol, 2002, 37(6): 375-536.
［61］Gasche Y, Soccal PM, Kanemitsu M, et al. Matrix metalloproteinases and diseases of the central nervous system with a special emphasis on ischemic brain［J］. Frontiers in Bioscience, 2006, 11(2): 1289-1301.
［62］Chang DI, Hosomi N, Lucero J, et al. Activation systems for latent matrix metalloproteinase-2 are upregulated immediately after focal cerebral ischemia［J］. J Cereb Blood Flow Metab, 2003, 23(12): 1408-1419.
［63］Munbryce S, Rosenberg GA. Matrix metalloproteinases in cerebrovascular disease［J］. J Cereb Blood Flow & Metab, 2005, 18(11): 1163-1172.
［64］Asahi M, Wang X, Mori T, et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia［J］. J Neuro Sci, 2001, 21(19): 7724-7732.
［65］Gidday JM,Gasche YG, Copin JC, et al. Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia［J］. Ajp Heart & Circulatory Physiology, 2005, 289(2): 558-568.
［66］Yang Y, Estrada EY, Thompson JF, et al. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat［J］. J Cereb Blood Flow Metab, 2007, 27(27): 697-709.
［67］Horstmann S, Kalb P, Koziol J, et al. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies［J］. Stroke, 2003, 34(9): 2165-2170.
［68］Vukasovic I, Tesijakuna A, Topic E, et al. Matrix metalloproteinases and their inhibitors in different acute stroke subtypes［J］. Clin Chem Lab Med, 2006, 44(4): 428-434.
［69］Montaner J, Molina CA, Monasterio J, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke［J］. Circulation, 2003, 107(4): 598-603.
［70］Maier CM, Hsieh L, Yu F, et al. Matrix metalloproteinase-9 and myeloperoxidase expression: quantitative analysis by antigen immunohistochemistry in a model of transient focal cerebral ischemia［J］. Stroke, 2004, 35(5): 1169-1174.
［71］Choi EY, Santoso S, Chavakis T. Mechanisms of neutrophil transendothelial migration［J］. Front Biosci, 2009, 14(5): 1596-1605.
［72］Nguyen HX, O'barr TJ, Anderson AJ. Polymorphonuclear leukocytes promote neurotoxicity through release of matrix metalloproteinases, reactive oxygen species, and TNF-alpha［J］. J Neurochem, 2007, 102(3): 900-912.
［73］Gu Z, Kaul M, Yan B, et al. S-nitrosylation of matrix metalloproteinases: Signaling pathway to neuronal cell death［J］. Science, 2002, 297(5584): 1186-1190.
［74］张浩. 转化生长因子β1通过ROS依赖的ERK-NF-KB通路对血管平滑肌细胞产生MMP9的影响［D］. 武汉大学, 2013.
［75］Long M, Park SG, Strickland I, et al. Nuclear factor-kappaB modulates regulatory T cell development by directly regulating expression of Foxp3 transcription factor［J］. Immunity, 2009, 31(6): 921-931.
［76］Pedros C, Gaud G, Bernard I, et al. An epistatic interaction between Themis1 and Vav1 modulates regulatory T cell function and inflammatory bowel disease development［J］. J Immunol, 2015, 195(4): 1608-1606.
［77］Kim EY, Moudgil KD. Immunomodulation of autoimmune arthritis by pro-inflammatory cytokines［J］. Cytokine, 2017 Apr 21. pii: S1043-4666(17)30097-2. doi: 10.1016/j.cyto.2017.04.012. ［Epub ahead of print］
［78］Housley WJ, Adams CO, Nichols FC, et al. Natural but not inducible regulatory T cells require TNF-alpha signaling for in vivo function［J］. J Immunol, 2011, 186(12): 6779-6787.
［79］Mccann FE, Perocheau DP, Ruspi G, et al. Selective tumor necrosis factor receptor I blockade is antiinflammatory and reveals immunoregulatory role of tumor necrosis factor receptor II in collagen-induced arthritis［J］. Arthritis Rheumatol, 2014, 66(10): 2728-2738.
［80］Sun L, Diamond ME, Ottaviano AJ, et al. Transforming growth factor-β1 promotes matrix metalloproteinase-9-mediated oral cancer invasion through snail expression［J］. Mol Cancer Res, 2008, 6(1): 10-20.
［81］Tobar N, Villar V, Santibanez JF. ROS-NFkappaB mediates TGF-β1-induced expression of urokinase-type plasminogen activator, matrix metalloproteinase-9 and cell invasion［J］. Mol Cell Biochem, 2010, 340(1/2): 195-202.
［82］Giacoppo S, Galuppo M, Iori R, et al. (RS)-glucoraphanin purified from Tuscan black kale and bioactivated with myrosinase enzyme protects against cerebral ischemia/reperfusion injury in rats［J］. Fitoterapia, 2014, 99: 166-177.
［83］Mao X, Wu Y, Diao H, et al. Interleukin-6 promotes systemic lupus erythematosus progression with Treg suppression approach in a murine systemic lupus erythematosus model［J］. Clin Rheumatol, 2014, 33(11): 1585-1593.
［84］Lee HT, Liu SP, Lin CH, et al. A crucial role of CXCL14 for promoting regulatory T cells activation in stroke［J］. Theranostics, 2017, 7(4): 855-875.
［85］Ren X, Akiyoshi K, Vandenbark A A, et al. CD4+FoxP3+ regulatory T-cells in cerebral ischemic stroke［J］. Metab Brain Dis, 2011, 26(1): 87-90.
［86］Kleinschnitz C, Wiendl H. Con: Regulatory T cells are protective in ischemic stroke［J］. Stroke, 2013, 44(8): e87-88.
［87］Li P, Gan Y, Sun BL, et al. Adoptive regulatory T-cell therapy protects against cerebral ischemia［J］. Ann Neurol, 2013, 74(3): 458-471.

[1]	ZHANG Xiaoling，GUAN Qiaobin，YANG Yi, GUO Li，HAN Chenyang. Effect of interleukin 12A on proliferation and differentiation of CD4+CD25+Foxp3+Treg [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 496-502.
[2]	YU Wan-jun, WANG Hua-ying, WENG Yue-song, SONG Yan-jin, GU Xiao, YING Hua-juan. Variation of CD₄^＋Foxp3^＋ regulatory T cells in sub-acute and chronic cigarette smoke exposure in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(6): 601-606.
[3]	ZOU Ming-zhi. Comparison of entecavir and adefovir dipivoxil on suppressing for the function of regulatory T cells for patients with chronic hepatitis B [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(6): 661-665.
[4]	WANG Shan-lin. Effects of aerosol imiquimod on the antigen-induced airway inflammation and Foxp3⁺ regulatory T cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(1): 33-37.